,source,page number,segment number,description,proposed_name,proposed_target,smiles,inchi,inchikey,validation
0,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,0,"S-217622 | CoV-2 Mpro
reversible SARS-CoV-2 3CLpro inhibitor
Ph. II/III candidate for COVID-19
virtual + HTS MS screen, SBDD
bioRxiv
Shionogi Pharmaceutical",S-217622 , CoV-2 Mpro,Cn1cnc(Cn2c(=O)[nH]/c(=N\c3cc4cn(C)nc4cc3Cl)n(Cc3cc(F)c(F)cc3F)c2=O)n1,"InChI=1S/C22H17ClF3N9O2/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24/h3-7,10H,8-9H2,1-2H3,(H,28,29,36)",QMPBBNUOBOFBFS-UHFFFAOYSA-N,True
1,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,1,"asundexian |  factor XI
factor XI inhibitor
Ph. II candidate for CV (fibrillation, stroke, MI) 
related to previous series
Br. J. Clin. Pharmacol.
Bayer AG",asundexian ,  factor XI,CC[C@@H](C(=O)Nc1ccc(C(N)=O)c(F)c1)n1cc(OC)c(-c2cc(Cl)ccc2-n2cc(C(F)(F)F)nn2)cc1=O,"InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40)/t19-/m0/s1",XYWIPYBIIRTJMM-IBGZPJMESA-N,True
2,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,2,"compound 1 | CD33 pre-mRNA
CD33 splicing modulator
preclinical (neurodegeneration)
from 3.1M cmpd phenotypic CD33 splicing screen 
ACS Med. Chem. Lett.
Pfizer Inc.",compound 1 , CD33 pre-mRNA,Cc1cnc2c(-c3ccc(C(=O)N(c4ncccc4C)[C@@H]4CCCNC4)cc3F)cnn2c1,"InChI=1S/C25H25FN6O/c1-16-12-29-24-21(14-30-31(24)15-16)20-8-7-18(11-22(20)26)25(33)32(19-6-4-9-27-13-19)23-17(2)5-3-10-28-23/h3,5,7-8,10-12,14-15,19,27H,4,6,9,13H2,1-2H3/t19-/m1/s1",YTRBUPKEYPDQGD-LJQANCHMSA-N,False
3,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,3,"GSK3640254 | HIV Gag
HIV maturation inhibitor
Ph. II candidate for HIV
from prior clinical candidate
Antimicrob. Agents Chemother.
ViiV Healthcare (GSK)",GSK3640254 , HIV Gag,[H][C@]12CC[C@@]3([H])[C@@](C)(CC[C@@]4(NCCN5CCS(=O)(=O)CC5)CC[C@@H](C(=C)C)[C@@]43[H])[C@]1(C)CC[C@@]1([H])C(C)(C)C(C3=CC[C@@](CF)(C(=O)O)CC3)=CC[C@]21C,"InChI=1S/C43H67FN2O4S/c1-29(2)31-12-19-43(45-22-23-46-24-26-51(49,50)27-25-46)21-20-40(6)33(36(31)43)8-9-35-39(5)15-13-32(38(3,4)34(39)14-16-41(35,40)7)30-10-17-42(28-44,18-11-30)37(47)48/h10,13,31,33-36,45H,1,8-9,11-12,14-28H2,2-7H3,(H,47,48)/t31-,33+,34-,35+,36+,39-,40+,41+,42+,43-/m0/s1",YFSNREBZTKMFEB-DHGHKPCRSA-N,True
4,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,4,"ADU-S100 | STING
STING agonist
Ph. II candidate for met. H&N cancer
from SBDD of endogenous ligand
Clin. Cancer Res.
Aduro (Chinook Therapeutics)",ADU-S100 , STING,[H][C@@]12COP(=O)(S)O[C@@]3([H])[C@@H](O)[C@]([H])(n4cnc5c(N)ncnc54)O[C@]3([H])COP(=O)(S)O[C@]([H])([C@@H]1O)[C@]([H])(n1cnc3c(N)ncnc31)O2,"InChI=1S/C20H24N10O10P2S2/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?/m1/s1",IZJJFUQKKZFVLH-ZILBRCNQSA-N,True
5,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,5,"MRTX1719 |  PRMT5-MTA
PRMT5 inhibitor
preclinical (MTAP-deleted cancers)
from fragment-based design + SBDD
J. Med. Chem.
Mirati Therapeutics",MRTX1719 ,  PRMT5-MTA,Cn1ncc(-c2ccc3c(=O)[nH]nc(CN)c3c2)c1-c1c(F)c(Cl)cc(OC2CC2)c1C#N,"InChI=1S/C23H18ClFN6O2/c1-31-22(20-15(8-26)19(33-12-3-4-12)7-17(24)21(20)25)16(10-28-31)11-2-5-13-14(6-11)18(9-27)29-30-23(13)32/h2,5-7,10,12H,3-4,9,27H2,1H3,(H,30,32)",BZKIOORWZAXIBA-UHFFFAOYSA-N,True
6,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,6,"compound 15 |  NaPi2b
NaPi2b inhibitor
preclinical (hyperphosphatemia)
in-house compound screen + optimization
J. Med. Chem.
Kyowa Kirin Co., Ltd.",compound 15 ,  NaPi2b,COCCN(CCOCCOCc1cccc(C(=O)Nc2sc3c(c2C(=O)N/N=C/c2ccc(Cl)c(C(F)(F)F)c2)CCC(C)(C)C3)c1)CC(=O)O,"InChI=1S/C36H42ClF3N4O7S/c1-35(2)10-9-26-29(19-35)52-34(31(26)33(48)43-41-20-23-7-8-28(37)27(18-23)36(38,39)40)42-32(47)25-6-4-5-24(17-25)22-51-16-15-50-14-12-44(11-13-49-3)21-30(45)46/h4-8,17-18,20H,9-16,19,21-22H2,1-3H3,(H,42,47)(H,43,48)(H,45,46)/b41-20+",FSSMGOIBVOBZSX-ZLNXIQNYSA-N,False
7,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,7,"DS-3801b | GPR38
GPR38 agonist
Ph. I candidate for chronic constipation
from previously disclosed GPR38 agonists 
Bioorg. Med. Chem. Lett.
Daiichi Sankyo Co., Ltd.",DS-3801b , GPR38,Cc1cc(N(C)C(=O)[C@H]2CC[C@H](Oc3cccc(CO)c3)CC2)ccc1CN1CCN[C@@H](C)C1.O=C(O)[C@@H](O)[C@@H](O)C(=O)O,"InChI=1S/C28H39N3O3.C4H6O6/c1-20-15-25(10-7-24(20)18-31-14-13-29-21(2)17-31)30(3)28(33)23-8-11-26(12-9-23)34-27-6-4-5-22(16-27)19-32;5-1(3(7)8)2(6)4(9)10/h4-7,10,15-16,21,23,26,29,32H,8-9,11-14,17-19H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t21-,23-,26-;1-,2+/m0./s1",ZTSLYJJVQMICOY-HCFLLYIRSA-N,False
8,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,8,"LEO 134310 | GR
glucocorticoid receptor agonist
Ph. I candidate for psoriasis
dual-soft drug
Sci. Rep.
LEO Pharma A/S",LEO 134310 , GR,C[C@H](NC(=O)[C@H]1CCCO1)[C@H](Oc1ccc(C(=O)O[C@H]2CCCN(C(=O)[C@H]3COC(=O)C3)C2)cc1)c1ccc(C2CC2)cc1,"InChI=1S/C34H40N2O8/c1-21(35-32(38)29-5-3-17-41-29)31(24-10-8-23(9-11-24)22-6-7-22)43-27-14-12-25(13-15-27)34(40)44-28-4-2-16-36(19-28)33(39)26-18-30(37)42-20-26/h8-15,21-22,26,28-29,31H,2-7,16-20H2,1H3,(H,35,38)/t21-,26+,28-,29+,31-/m0/s1",NADMBBGHEQYUMJ-WDXNIXBWSA-N,True
9,4-MOTM-Infographic-PDF-Summaries-Tables-for-Download.pdf,0,9,"ATA-101  | α-7 nAChR
alpha-7 nicotinic receptor agonist
Ph. II candidate for chronic cough
drug repurposing
J. Pharmacol. Exp. Ther.
Johns Hopkins",ATA-101  , α-7 nAChR,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1,"InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21+/m0/s1",OXKRFEWMSWPKKV-GHTZIAJQSA-N,True
10,6-MOTM-Infographic-FEBRUARY.pdf,0,0,"BMS-820132 | GK
oral GK partial activator
Ph. I candidate for diabetes
from HTS of BMS collection and SBDD
J. Med. Chem.
Bristol Myers Squibb",BMS-820132 , GK,CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3cnc(C(=O)N4CCC4)cn3)cc(OC(C)C)c2)n1)OCC,"InChI=1S/C26H33N6O7P/c1-5-36-40(35,37-6-2)17-32-11-8-23(30-32)29-25(33)19-12-20(38-18(3)4)14-21(13-19)39-24-16-27-22(15-28-24)26(34)31-9-7-10-31/h8,11-16,18H,5-7,9-10,17H2,1-4H3,(H,29,30,33)",OYUDYQMFVRHPIY-UHFFFAOYSA-N,True
11,6-MOTM-Infographic-FEBRUARY.pdf,0,1,"Compound 14f | ChemR23
oral ChemR23 inhibitor
preclinical, immunology
from HTS, scaffold hopping and opt.
Bioorg. Med. Chem.
Kyowa Kirin",Compound 14f , ChemR23,Cc1ccc(-c2nc(=O)o[nH]2)c(-c2ccc([C@@H](C)N(CC3CC3)c3nc(C(=O)NS(=O)(=O)C4CC4)c(C4CC4)s3)cc2)c1,"InChI=1S/C31H33N5O5S2/c1-17-3-14-24(28-33-31(38)41-34-28)25(15-17)21-8-6-20(7-9-21)18(2)36(16-19-4-5-19)30-32-26(27(42-30)22-10-11-22)29(37)35-43(39,40)23-12-13-23/h3,6-9,14-15,18-19,22-23H,4-5,10-13,16H2,1-2H3,(H,35,37)(H,33,34,38)/t18-/m1/s1",FQGLCYYIHLNVRG-GOSISDBHSA-N,True
12,6-MOTM-Infographic-FEBRUARY.pdf,0,2,"GCC5694A | SGLT2
oral SGLT2 inhibitor
clinical candidate for diabetes
from literature SGLT2 inhibitor
Bioorganic Med. Chem. Lett.
GC Pharma (Green Cross)",GCC5694A , SGLT2,OC[C@H]1O[C@@H](c2cc(Cc3ccc(C4CC4)cc3)c(Cl)c3c2CCO3)[C@H](O)[C@@H](O)[C@@H]1O,"InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1",KORCWPOBTZTAFI-YVTYUBGGSA-N,True
13,6-MOTM-Infographic-FEBRUARY.pdf,0,3,"LY3154885 | D1
oral D1 modulator
Ph. I candidate for neurological disorders
opt. against DDI w/ hepatocyte Cl assay
J. Med. Chem.
Eli Lilly and Company",LY3154885 , D1,C[C@H]1c2cccc(-c3cnn(C)c3)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl,"InChI=1S/C23H23Cl2N3O2/c1-14-17-5-3-6-18(15-11-26-27(2)12-15)19(17)9-16(13-29)28(14)23(30)10-20-21(24)7-4-8-22(20)25/h3-8,11-12,14,16,29H,9-10,13H2,1-2H3/t14-,16+/m0/s1",MJDOWJUPBHLXIH-GOEBONIOSA-N,True
14,6-MOTM-Infographic-FEBRUARY.pdf,0,4,"Danavorexton | OX2
injectable OX2 agonist
Ph. I candidate for narcolepsy
from HTS and optimization
ACS Med. Chem. Lett.
Takeda",Danavorexton , OX2,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@@H](c2ccccc2)CC1,"InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17-,18+,19-,20-/m0/s1",UXZAJSZFFARTEI-YRPNKDGESA-N,True
15,6-MOTM-Infographic-FEBRUARY.pdf,0,5,"AZ13824374 | ATAD2
in vitro ATAD2 inhibitor
preclinical, oncology
from 1.8 million compound HTS and opt.
J. Med. Chem.
AstraZeneca",AZ13824374 , ATAD2,CC(=O)C1=NN2C(C)=NN=C2C(NC2CCN(CC(C)(C)F)CC2)=C1.CC1(C)[CH]23N4C5C6=C(C=CC=C6)C[CH]46C(=O)N[CH]512(C)N3C6=O,,,False
16,6-MOTM-Infographic-FEBRUARY.pdf,0,6,"ASP5878 | FGFR
oral FGFR inhibitor
Ph. I candidate for solid tumors
opt. from previously disclosed lead
Bioorg. Med. Chem.
Astellas Pharma Inc.",ASP5878 , FGFR,COc1cc(OC)c(F)c(COc2cnc(Nc3cnn(CCO)c3)nc2)c1F,"InChI=1S/C18H19F2N5O4/c1-27-14-5-15(28-2)17(20)13(16(14)19)10-29-12-7-21-18(22-8-12)24-11-6-23-25(9-11)3-4-26/h5-9,26H,3-4,10H2,1-2H3,(H,21,22,24)",VDZZYOJYLLNBTD-UHFFFAOYSA-N,True
17,6-MOTM-Infographic-FEBRUARY.pdf,0,7,"AZD7648 | DNA-PK
oral DNA-PK inhibitor
Ph. I/II candidate for advanced tumors
from screening for selectivity vs. PI3Ka
Mol. Cancer Ther.
AstraZeneca",AZD7648 , DNA-PK,Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C,"InChI=1S/C18H20N8O2/c1-11-7-15-20-10-21-25(15)9-13(11)22-17-19-8-14-16(23-17)26(18(27)24(14)2)12-3-5-28-6-4-12/h7-10,12H,3-6H2,1-2H3,(H,19,22,23)",XISVSTPEXYIKJL-UHFFFAOYSA-N,True
18,6-MOTM-Infographic-FEBRUARY.pdf,0,8,"T-690 | GCS
oral GCS inhibitor
preclinical, neurodegeneration
scaffold hop from prev. reported GCS inhibitor
J. Med. Chem.
Takeda",T-690 , GCS,CC(C)(O)c1ccc(NC(=O)c2ccnn(-c3ccccc3OCC(F)(F)F)c2=O)cc1,"InChI=1S/C22H20F3N3O4/c1-21(2,31)14-7-9-15(10-8-14)27-19(29)16-11-12-26-28(20(16)30)17-5-3-4-6-18(17)32-13-22(23,24)25/h3-12,31H,13H2,1-2H3,(H,27,29)",CQAPXPSWLDAVEG-UHFFFAOYSA-N,True
19,6-MOTM-Infographic-FEBRUARY.pdf,0,9,"MAP855 | MEK1/2
oral MEK1/2 inhibitor
preclinical, oncology
from HTS and SBDD
J. Med. Chem.
Novartis Institutes for BioMedical Research",MAP855 , MEK1/2,Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1[C@H]1CCN(C(=O)CO)C[C@@H]1F,"InChI=1S/C28H23ClF2N6O3/c1-15-35-24-12-34-23-11-21(30)18(17-4-3-16(9-20(17)29)40-28-32-6-2-7-33-28)10-19(23)27(24)37(15)25-5-8-36(13-22(25)31)26(39)14-38/h2-4,6-7,9-12,22,25,38H,5,8,13-14H2,1H3/t22-,25-/m0/s1",WZZBNLYBHUDSHF-DHLKQENFSA-N,True
20,MOTM-Infographic-MARCH-2022-v2.pdf,0,0,"rilzabrutinib (PRN1008) | BTK
oral reversible covalent BTK inhibitor
in Ph. III for immune thrombocytopenia
from structure-based drug design + opt.
J. Med. Chem.
Principia Biopharma (Sanofi), So. San Francisco, CA",rilzabrutinib (PRN1008) , BTK,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,"InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1",LCFFREMLXLZNHE-GBOLQPHISA-N,True
21,MOTM-Infographic-MARCH-2022-v2.pdf,0,1,"INE963 | Pf 3D7
oral blood stage antimalarial
in Ph. I (healthy volunteers)
from 1.5M cmpd phenotypic screen + opt.
J. Med. Chem.
Novartis (NIBR), Emeryville, CA",INE963 , Pf 3D7,COc1nc(C(C)C)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12,"InChI=1S/C19H26N6O2S/c1-12(2)14-5-4-13(16(22-14)27-3)15-10-21-17-25(15)23-18(28-17)24-8-6-19(26,11-20)7-9-24/h4-5,10,12,26H,6-9,11,20H2,1-3H3",JYHSRMKXBAPFST-UHFFFAOYSA-N,True
22,MOTM-Infographic-MARCH-2022-v2.pdf,0,2,"ulevostinag (MK-1454) | STING
intratumoral STING agonist
in Ph. II for met. HNSCC
cyclic dinucleotide derivative
J. Med. Chem.
Merck, Kenilworth, NJ",ulevostinag (MK-1454) , STING,NC1=NC2=C(N=CN2[CH]23OC(COP(=O)(S)OC4C(COP(=O)S)OC5[CH]4(F)N54C=NC5=C4N=CNC5=O)[CH]4(F)C2OC43)C(=O)N1,,,False
23,MOTM-Infographic-MARCH-2022-v2.pdf,0,3,"compound 24 | KIF18A
oral kinesin motor protein inhibitor
relative AMG 650 in Ph. I for cancer
from ~600k compounds HTS + opt
J. Med. Chem.
Amgen, Thousand Oaks, CA",compound 24 , KIF18A,CC(C)(C)NS(=O)(=O)C1=CC(=CC=C1)NC(=O)C2=CC=C(C=C2N3CCC4(CC4)CC3)NS(=O)(=O)C5(C)CC5,"InChI=1S/C28H38N4O5S2/c1-26(2,3)31-38(34,35)22-7-5-6-20(18-22)29-25(33)23-9-8-21(30-39(36,37)27(4)10-11-27)19-24(23)32-16-14-28(12-13-28)15-17-32/h5-9,18-19,30-31H,10-17H2,1-4H3,(H,29,33)",MZGYQJDGUVDYIK-UHFFFAOYSA-N,True
24,MOTM-Infographic-MARCH-2022-v2.pdf,0,4,"compound 10 | PPARγ
oral PPARg phosphorylation inhibitor, partial 
agonist
efficacy in diabetic mouse model
from structure-based virtual screen
ACS Med. Chem. Lett.
AstraZeneca, Gothenburg, SE",compound 10 , PPARγ,O=C(O)c1nn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cc(Oc3ccccc3)ccc12,"InChI=1S/C22H14Cl2N2O4/c23-18-9-6-13(10-19(18)24)12-26-21(27)17-11-15(30-14-4-2-1-3-5-14)7-8-16(17)20(25-26)22(28)29/h1-11H,12H2,(H,28,29)",IQKNCBUBONVBNJ-UHFFFAOYSA-N,True
25,MOTM-Infographic-MARCH-2022-v2.pdf,0,5,"etavopivat | PKR
oral pyruvate kinase activator
in Ph. II/III for genetic anemias
200 or 400 mg QD, follows etavopivat
J Pharmacol Exp Ther.
Forma Therapeutics, Watertown, MA",etavopivat , PKR,O=C([C@H](CO)c1ccccc1)N1CC2=C(C1)CN(S(=O)(=O)c1cnc3c(c1)OCCO3)C2,"InChI=1S/C22H23N3O6S/c26-14-19(15-4-2-1-3-5-15)22(27)24-10-16-12-25(13-17(16)11-24)32(28,29)18-8-20-21(23-9-18)31-7-6-30-20/h1-5,8-9,19,26H,6-7,10-14H2/t19-/m1/s1",KZFFYEPYCVDOGE-LJQANCHMSA-N,True
26,MOTM-Infographic-MARCH-2022-v2.pdf,0,6,"BMS-986176/LX-9211 | AAK1
oral CNS-penetrant AAK1 kinase inhibitor
in Ph. II for neuropathic pain
from high-throughput screen + opt.
J. Med. Chem.
Bristol-Myers Squibb, Wallingford, CT",BMS-986176/LX-9211 , AAK1,CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)nc1C(F)F,"InChI=1S/C19H23F4N3O/c1-11(2)9-19(3,24)10-27-15-5-4-13(26-16(15)18(22)23)12-6-7-25-14(8-12)17(20)21/h4-8,11,17-18H,9-10,24H2,1-3H3/t19-/m0/s1",RKAHOQATMSONTM-IBGZPJMESA-N,True
27,MOTM-Infographic-MARCH-2022-v2.pdf,0,7,"branaplam | SMN2
oral, CNS-penetrant splicing modulator 
w/ HTT activity
in Ph. II for Huntington’s (prev. SMA)
further characterization of SMA candidate
Nat. Commun.
Novartis, Cambridge, MA",branaplam , SMN2,CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1,"InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)",STWTUEAWRAIWJG-UHFFFAOYSA-N,True
28,MOTM-Infographic-MARCH-2022-v2.pdf,0,8,"MAK683 | PRC2 (EED subunit)
oral, allosteric PRC2 inhibitor (EED)
in Ph. I/II for cancer (DLBCL); preliminary efficacy
from micromolar HTS hit
J. Med. Chem.
Novartis, Emeryville, CA",MAK683 , PRC2 (EED subunit),Cc1ncccc1-c1cnc(NCc2c(F)ccc3c2CCO3)n2cnnc12,"InChI=1S/C20H17FN6O/c1-12-13(3-2-7-22-12)16-10-24-20(27-11-25-26-19(16)27)23-9-15-14-6-8-28-18(14)5-4-17(15)21/h2-5,7,10-11H,6,8-9H2,1H3,(H,23,24)",XLIBABIFOBYHSV-UHFFFAOYSA-N,True
29,MOTM-Infographic-MARCH-2022-v2.pdf,0,9,"HR1405-01 | COX
intravenous NSAID
faster Tmax and lower dose vs. loxoprofen in Ph. I
from loxoprofen metabolite
Eur. J. Med. Chem.
Nanjing Heron Pharmaceutical Co., Nanjing, CN",HR1405-01 , COX,C[C@H](C(=O)O)c1ccc(C[C@H]2CCC[C@@H]2O)cc1,"InChI=1S/C15H20O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13-14,16H,2-4,9H2,1H3,(H,17,18)/t10-,13+,14-/m0/s1",SHAHPWSYJFYMRX-GDLCADMTSA-N,True
30,MOTM-Infographic-April-2022-1.pdf,0,0,"JDQ443 | KRASG12C
oral KRASG12C inhibitor 
Ph. III candidate for NSCLC
from de novo SBDD in SWII pocket
Cancer Discov.
Novartis, Basel, CH",JDQ443 , KRASG12C,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,"InChI=1S/C29H28ClN7O/c1-5-24(38)36-14-29(15-36)10-20(11-29)37-17(3)25(26-21-13-31-33-22(21)8-16(2)27(26)30)28(34-37)18-6-7-23-19(9-18)12-32-35(23)4/h5-9,12-13,20H,1,10-11,14-15H2,2-4H3,(H,31,33)",AZUYLZMQTIKGSC-UHFFFAOYSA-N,True
31,MOTM-Infographic-April-2022-1.pdf,0,1,"AZD4625 | KRASG12C
oral KRASG12C inhibitor 
oral efficacy in xenograft mice
from literature starting point and SBDD
J. Med. Chem.
AstraZeneca, Cambridge, UK",AZD4625 , KRASG12C,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,"InChI=1S/C24H21ClF2N4O3/c1-3-16(33)30-10-13-7-8-34-23-19-22(28-11-29-24(19)31(13)9-12(30)2)21(27)18(20(23)25)17-14(26)5-4-6-15(17)32/h3-6,11-13,32H,1,7-10H2,2H3/t12-,13+/m1/s1",KYVBBJIEKCCZTM-OLZOCXBDSA-N,True
32,MOTM-Infographic-April-2022-1.pdf,0,2,"JBJ-09-063 | EGFR
allosteric mutant-EGFR inhibitor
in vivo efficacy in osimertinib-resistant 
xenograft models
from opt. of prev. disclosed EGFR inhibitor
Nat. Cancer
Dana-Farber Cancer Institute, Boston, MA",JBJ-09-063 , EGFR,CN1CCC(c2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)Nc3nccs3)c3cc(F)ccc3O)C4)cc2)CC1,"InChI=1S/C31H29FN4O3S/c1-35-13-10-21(11-14-35)19-2-4-20(5-3-19)22-6-7-23-18-36(30(39)25(23)16-22)28(26-17-24(32)8-9-27(26)37)29(38)34-31-33-12-15-40-31/h2-9,12,15-17,21,28,37H,10-11,13-14,18H2,1H3,(H,33,34,38)",SYTVDTWRIZNVEW-UHFFFAOYSA-N,True
33,MOTM-Infographic-April-2022-1.pdf,0,3,"ABBV-318 | NaV1.7/1.8
oral CNS-penetrant Nav1.7/1.8 blocker
in vivo efficacy in rodent pain models
electrophysiology-based HTS and opt.
Bioorg. Med. Chem.
AbbVie, North Chicago, IL",ABBV-318 , NaV1.7/1.8,O=C(c1ccc2cc(Oc3ccc(C(F)(F)F)cn3)ccc2n1)N1CC[C@@H](F)C1,"InChI=1S/C20H15F4N3O2/c21-14-7-8-27(11-14)19(28)17-4-1-12-9-15(3-5-16(12)26-17)29-18-6-2-13(10-25-18)20(22,23)24/h1-6,9-10,14H,7-8,11H2/t14-/m1/s1",FWLFRXVPNVBXGR-CQSZACIVSA-N,True
34,MOTM-Infographic-April-2022-1.pdf,0,4,"tenapanor | NHE3
oral gut-restricted Na+/H+ exchanger inhibitor
FDA-approved IBS treatment
from literature starting point and opt
ACS Med. Chem. Lett.
Ardelyx Inc., Fremont, CA/Waltham, MA",tenapanor , NHE3,CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1,"InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1",DNHPDWGIXIMXSA-CXNSMIOJSA-N,True
35,MOTM-Infographic-April-2022-1.pdf,0,5,"lenrispodun (ITI-214) | PDE1
oral, CNS-penetrant, picomolar PDE1 inhibitor
Ph. I/II in neurology and heart failure
from literature starting point, LBDD and SBDD
Neuropsychopharmacology
Intra-Cellular Therapies, New York, NY",lenrispodun (ITI-214) , PDE1,[H][C@@]12CCC[C@]1([H])N1C(=N2)N(C)C(=O)c2c1nn(Cc1ccc(-c3cccc(F)n3)cc1)c2Nc1ccccc1,"InChI=1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3/t22-,23+/m1/s1",BBIPVJCGIASXJB-PKTZIBPZSA-N,True
36,MOTM-Infographic-April-2022-1.pdf,0,6,"compound 41 | WDR5
oral WDR5 inhibitor
pM Ki, nanomolar in cells
from FBDD, SBDD, and PK opt.
J. Med. Chem.
Vanderbilt University School of Medicine, 
Nashville, TN",compound 41 , WDR5,CCn1cc(-c2cc(Cn3ccnc3)cc3c2CCN([C@H](c2cc(C)ccn2)C2CC2)C3=O)c(C(F)(F)F)n1,"InChI=1S/C29H29F3N6O/c1-3-37-16-24(27(35-37)29(30,31)32)22-13-19(15-36-11-9-33-17-36)14-23-21(22)7-10-38(28(23)39)26(20-4-5-20)25-12-18(2)6-8-34-25/h6,8-9,11-14,16-17,20,26H,3-5,7,10,15H2,1-2H3/t26-/m0/s1",FFUQRXFVTVBZMZ-SANMLTNESA-N,True
37,MOTM-Infographic-April-2022-1.pdf,0,7,"DS69910557 | hPTHR1
oral hPTHR1 GPCR antagonist
calcium-lowering activity in rodent
scaffold-hopping from lit. starting point
Bioorg. Med. Chem.
Daiichi Sankyo, Tokyo, JP",DS69910557 , hPTHR1,CC1(C)C(=O)N(c2ccc(N3CC(F)(CN[C@@H]4CC[C@@H](C(=O)O)CC4)C3)cc2)c2cc(Cl)ccc2-c2cc(Cl)cnc21,"InChI=1S/C32H33Cl2FN4O3/c1-31(2)28-26(13-21(34)15-36-28)25-12-5-20(33)14-27(25)39(30(31)42)24-10-8-23(9-11-24)38-17-32(35,18-38)16-37-22-6-3-19(4-7-22)29(40)41/h5,8-15,19,22,37H,3-4,6-7,16-18H2,1-2H3,(H,40,41)/t19-,22-",JAOGFYSXDYNYSX-XYWHTSSQSA-N,False
38,MOTM-Infographic-April-2022-1.pdf,0,8,"compound 14 | HIV-1 protease
potent HIV-1 protease inhibitor
in vitro activity (IC50= 0.0071 μM, EC50= 0.86 μM)
from “pocket-to-lead” virtual screen and SBDD
J. Med. Chem.
Shionogi, Osaka, JP",compound 14 , HIV-1 protease,COc1ccc(CN2C[C@H](O)[C@@](CCC(C)C)(c3ccc(S(C)(=O)=O)cc3O[C@@H](C)CO)C2=O)cc1,"InChI=1S/C27H37NO7S/c1-18(2)12-13-27(23-11-10-22(36(5,32)33)14-24(23)35-19(3)17-29)25(30)16-28(26(27)31)15-20-6-8-21(34-4)9-7-20/h6-11,14,18-19,25,29-30H,12-13,15-17H2,1-5H3/t19-,25-,27+/m0/s1",QQVYMLIPGZJSRF-YDOVEJIGSA-N,True
39,MOTM-Infographic-April-2022-1.pdf,0,9,"compound 53 | STING
non-nucleotide STING agonist
novel mechanism for STING activation
from micromolar HTS hit
Nature
University of Texas Southwestern 
Medica Center, Dallas, TX",compound 53 , STING,CC1(C)C(=O)N(Cc2c(F)cccc2Cl)c2cc(C(=O)NCc3c(F)cc(F)cc3F)ccc21,"InChI=1S/C25H19ClF4N2O2/c1-25(2)17-7-6-13(23(33)31-11-15-20(29)9-14(27)10-21(15)30)8-22(17)32(24(25)34)12-16-18(26)4-3-5-19(16)28/h3-10H,11-12H2,1-2H3,(H,31,33)",OEBVYNULNKSONR-UHFFFAOYSA-N,True
40,MOTM-Infographic-MAY.pdf,0,0,"Pevonedistat | NEDD8-activating 
enzyme (NAE)
intravenous NEDD8-activating enzyme inhibitor
Ph. III candidate for oncology
from HTS and optimization
Drug Metab. Dispos.
Takeda, Lexington, MA",Pevonedistat , NEDD8-activating ,NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,"InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1",MPUQHZXIXSTTDU-QXGSTGNESA-N,True
41,MOTM-Infographic-MAY.pdf,0,1,"Compound 20 | α5-GABAA
oral α5-GABAA receptor NAM
oral efficacy in CIAS rodent models
scaffold hopping from literature starting point
J. Med. Chem.
Gedeon Richter, Budapest, HU",Compound 20 , α5-GABAA,Cc1onc(-c2ccc(F)cc2)c1COc1ccc2c(n1)CCN(C(=O)CS(C)(=O)=O)C2,"InChI=1S/C22H22FN3O5S/c1-14-18(22(25-31-14)15-3-6-17(23)7-4-15)12-30-20-8-5-16-11-26(10-9-19(16)24-20)21(27)13-32(2,28)29/h3-8H,9-13H2,1-2H3",GTVLCHCOKLXHLY-UHFFFAOYSA-N,True
42,MOTM-Infographic-MAY.pdf,0,2,"NVP-CLR457 | pan-class IA PI3K
oral pan-class IA PI3K inhibitor
Ph. I in advanced solid tumors
opt. from previous clinical candidate
J. Med. Chem.
Novartis (NIBR), Basel, CH",NVP-CLR457 , pan-class IA PI3K,C[C@H]1OC(=O)N(c2cc(-c3cnc(N)nc3C(F)(F)F)nc(N3CCOCC3)n2)[C@H]1CO,"InChI=1S/C18H20F3N7O4/c1-9-12(8-29)28(17(30)32-9)13-6-11(24-16(25-13)27-2-4-31-5-3-27)10-7-23-15(22)26-14(10)18(19,20)21/h6-7,9,12,29H,2-5,8H2,1H3,(H2,22,23,26)/t9-,12+/m1/s1",IEYOHYVYEJVEJJ-SKDRFNHKSA-N,True
43,MOTM-Infographic-MAY.pdf,0,3,"TXA6101 | FtsZ
gram-negative FtsZ inhibitor
In vitro efficacy against E. coli
Literature starting point and opt
J. Antibiot.
TAXIS Pharmaceuticals, Monmouth Junction, NJ",TXA6101 , FtsZ,NC(=O)c1c(F)ccc(OCc2nc(-c3ccc(C(F)(F)F)cc3)c(Br)o2)c1F,"InChI=1S/C18H10BrF5N2O3/c19-16-15(8-1-3-9(4-2-8)18(22,23)24)26-12(29-16)7-28-11-6-5-10(20)13(14(11)21)17(25)27/h1-6H,7H2,(H2,25,27)",ONGPJYSSZQHFBU-UHFFFAOYSA-N,True
44,MOTM-Infographic-MAY.pdf,0,4,"RLX-33 | RXFP3
intraperitoneal Relaxin-3/RXFP3 antagonist
in vivo efficacy in induced food intake rats models
from 19000 compound HTS and opt.
J. Med. Chem.
Research Triangle Institute, Durham, NC",RLX-33 , RXFP3,O=C(Nc1ccc(-c2nc(-c3ccc(Cl)cc3)no2)cc1)C1CC(=O)N(Cc2ccco2)C1,"InChI=1S/C24H19ClN4O4/c25-18-7-3-15(4-8-18)22-27-24(33-28-22)16-5-9-19(10-6-16)26-23(31)17-12-21(30)29(13-17)14-20-2-1-11-32-20/h1-11,17H,12-14H2,(H,26,31)",LTOAWFRZXVPHAJ-UHFFFAOYSA-N,False
45,MOTM-Infographic-MAY.pdf,0,5,"INCB13739 | 11β-HSD1
oral tissue-targeting 11β-HSD1 inhibitor
Ph. II in T2DM/obesity completed (QD)
scaffold-hopping from cortisone 
and prior 11β-HSD1 inh.
Bioorg. Med. Chem. Lett.
Incyte Research Institute, Wilmington, DE",INCB13739 , 11β-HSD1,CNC(=O)c1ccc(-c2ccc(C3(C(=O)N4CCC5(C4)OC(=O)c4ccccc45)CC3)cc2)cn1,"InChI=1S/C28H25N3O4/c1-29-24(32)23-11-8-19(16-30-23)18-6-9-20(10-7-18)27(12-13-27)26(34)31-15-14-28(17-31)22-5-3-2-4-21(22)25(33)35-28/h2-11,16H,12-15,17H2,1H3,(H,29,32)",BDQCDIWFPIDPQU-UHFFFAOYSA-N,True
46,MOTM-Infographic-MAY.pdf,0,6,"Compound 4e | p38α/β MAPK
inhaled p38α/β MAPK inhibitor
effective in the rat LPS-induced lung inflamm. model
SBDD and focus on slow dissociation kinetics
J. Med. Chem.
Chiesi Farmaceutici, Parma, IT",Compound 4e , p38α/β MAPK,C[C@H]1CCCCN1c1nnc2ccc(O[C@@H]3CC[C@H](NC(=O)Nc4cc(C(C)(C)C)nn4-c4cnn(CCN(C)C)c4)c4ccccc43)cn12,"InChI=1S/C37H49N11O2/c1-25-11-9-10-18-46(25)36-42-41-33-17-14-27(24-47(33)36)50-31-16-15-30(28-12-7-8-13-29(28)31)39-35(49)40-34-21-32(37(2,3)4)43-48(34)26-22-38-45(23-26)20-19-44(5)6/h7-8,12-14,17,21-25,30-31H,9-11,15-16,18-20H2,1-6H3,(H2,39,40,49)/t25-,30-,31+/m0/s1",PPZSTJQLZOPKBO-LGXAAPQCSA-N,True
47,MOTM-Infographic-MAY.pdf,0,7,"MAGLi 432 | MAGL
CNS penetrant, intraperitoneal, reversible MAGL inh.
in vivo target engagement in brain but lack of efficacy
from opt. of a screening hit
bioRxiv
Roche, Basel, CH",MAGLi 432 , MAGL,[H][C@]12CC[C@H](c3ccc(Cl)cc3)CN1CCN(C(=O)c1cccc(OC)c1Br)C2,"InChI=1S/C22H24BrClN2O2/c1-28-20-4-2-3-19(21(20)23)22(27)26-12-11-25-13-16(7-10-18(25)14-26)15-5-8-17(24)9-6-15/h2-6,8-9,16,18H,7,10-14H2,1H3/t16-,18+/m0/s1",BKTASVDLNMGMFP-FUHWJXTLSA-N,True
48,MOTM-Infographic-MAY.pdf,0,8,"Sudapyridine (WX-081) | 
mycobacterial ATP-Synthase
oral ATP-synthase inhibitor
Ph. I candidate for pulmonary tuberculosis
toxicol. risk mitigation from prev. disclosed inhibitor
Bioorg. Med. Chem. Lett.
WuXi AppTec, Shanghai, CN",Sudapyridine (WX-081) , ,COc1ncc(-c2ccc(Cl)cc2)cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,"InChI=1S/C34H33ClN2O2/c1-37(2)21-20-34(38,31-15-9-13-25-10-7-8-14-29(25)31)32(26-11-5-4-6-12-26)30-22-27(23-36-33(30)39-3)24-16-18-28(35)19-17-24/h4-19,22-23,32,38H,20-21H2,1-3H3/t32-,34-/m1/s1",MMUCHWPQRGEHDV-ZFEZZJPFSA-N,False
49,MOTM-Infographic-MAY.pdf,0,9,"Dorzagliatin | Glucokinase
oral allosteric glucokinase activator
Ph. III candidate in T2DM
HbA1c reduction vs placebo
Nat. Med.
Hua Medicine, Shanghai, CN",Dorzagliatin , Glucokinase,CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=O,"InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1",HMUMWSORCUWQJO-QAPCUYQASA-N,True
50,MOTM-Infographic-JUNE.pdf,0,0,"Compound 23 | IL-17A
oral interleukin 17A modulator
favorable in vivo PK profile in multiple species
from a previous patent and SBDD
J. Med. Chem.
LEO Pharma Research & Early Development,
Ballerup, DK",Compound 23 , IL-17A,Cc1n[nH]c(C)c1-c1ccc(NC(=O)[C@@H](NC(=O)c2ccnn2C(C)C)C(C2CC2)C2CC2)cc1,"InChI=1S/C27H34N6O2/c1-15(2)33-22(13-14-28-33)26(34)30-25(24(19-5-6-19)20-7-8-20)27(35)29-21-11-9-18(10-12-21)23-16(3)31-32-17(23)4/h9-15,19-20,24-25H,5-8H2,1-4H3,(H,29,35)(H,30,34)(H,31,32)/t25-/m0/s1",CQKVACARDGYEMU-VWLOTQADSA-N,True
51,MOTM-Infographic-JUNE.pdf,0,1,"BMS-986120 | PAR4
oral PAR4 antagonist
Ph. II completed in thrombosis (discontinued)
HTS, potency, and PK opt.
J. Med. Chem.
Bristol-Myers Squibb, Princeton, NJ",BMS-986120 , PAR4,COc1cc(OCc2nc(N3CCOCC3)sc2C)c2cc(-c3cn4nc(OC)sc4n3)oc2c1,"InChI=1S/C23H23N5O5S2/c1-13-17(25-21(34-13)27-4-6-31-7-5-27)12-32-18-8-14(29-2)9-19-15(18)10-20(33-19)16-11-28-22(24-16)35-23(26-28)30-3/h8-11H,4-7,12H2,1-3H3",MINMDCMSHDBHKG-UHFFFAOYSA-N,True
52,MOTM-Infographic-JUNE.pdf,0,2,"EZM0414 | SETD2
oral SETD2 Inhibitor
Ph. I candidate in oncology
in-house library screening and SBDD
ACS Med. Chem. Lett.
Epizyme Inc., Cambridge, MA",EZM0414 , SETD2,CC(=O)N1CCN([C@H]2CCC[C@@H](NC(=O)c3cc4c(F)ccc(C)c4[nH]3)C2)CC1,"InChI=1S/C22H29FN4O2/c1-14-6-7-19(23)18-13-20(25-21(14)18)22(29)24-16-4-3-5-17(12-16)27-10-8-26(9-11-27)15(2)28/h6-7,13,16-17,25H,3-5,8-12H2,1-2H3,(H,24,29)/t16-,17+/m1/s1",PGNLXEBQMQHFNK-SJORKVTESA-N,True
53,MOTM-Infographic-JUNE.pdf,0,3,"DNL201 | LRRK2
oral LRRK2 kinase inhibitor
Ph. I completed in Parkinson’s Disease
HTS, SBDD, and CNS-focused opt.
Sci. Transl. Med.
Denali Therapeutics Inc., South San Francisco, CA",DNL201 , LRRK2,CNc1nc(Nc2cn(C(C)(C)C#N)nc2C)ncc1C(F)(F)F,"InChI=1S/C14H16F3N7/c1-8-10(6-24(23-8)13(2,3)7-18)21-12-20-5-9(14(15,16)17)11(19-4)22-12/h5-6H,1-4H3,(H2,19,20,21,22)",ZPPUMAMZIMPJGP-UHFFFAOYSA-N,True
54,MOTM-Infographic-JUNE.pdf,0,4,"Iclepertin | GlyT1
oral GlyT1 inhibitor
Ph. III candidate in schizophrenia
10 and 25 mg PO QD efficacy in CIAS improv.
J. Pharmacol. Exp. Ther.
Boehringer Ingelheim Pharma, Biberach 
an der Riss, DE",Iclepertin , GlyT1,[H][C@]12CN(C(=O)c3cc(S(C)(=O)=O)ccc3O[C@H](C)C(F)(F)F)C[C@@]1(c1cc(C(F)(F)F)on1)C2,"InChI=1S/C20H18F6N2O5S/c1-10(19(21,22)23)32-14-4-3-12(34(2,30)31)5-13(14)17(29)28-8-11-7-18(11,9-28)15-6-16(33-27-15)20(24,25)26/h3-6,10-11H,7-9H2,1-2H3/t10-,11+,18+/m1/s1",MYHDQTVHHMSLEF-DDBGAENHSA-N,True
55,MOTM-Infographic-JUNE.pdf,0,5,"BMS-986339 | FXR
oral nonbile acid FXR agonist
FGF15 induction in a BDL mouse model
SBDD
J. Med. Chem.
Biocon-Bristol Myers Squibb Research 
and Development Center, Bangalore, IN",BMS-986339 , FXR,CC(C)(C1=NC(=NO1)C23CCC(CC2)(CC3)CN(C4=CC=CC(=C4)C5=CC=C(C=C5)C(C)(C)O)C(=O)[C@H]6C[C@@](C6)(C(F)(F)F)O)F,"InChI=1S/C35H41F4N3O4/c1-30(2,36)29-40-28(41-46-29)33-15-12-32(13-16-33,14-17-33)21-42(27(43)24-19-34(45,20-24)35(37,38)39)26-7-5-6-23(18-26)22-8-10-25(11-9-22)31(3,4)44/h5-11,18,24,44-45H,12-17,19-21H2,1-4H3/t24-,32?,33?,34+",AEMZJBZKICOPPC-RNMMDBENSA-N,True
56,MOTM-Infographic-JUNE.pdf,0,6,"MK-0159 | CD38
oral CD38 inhibitor
in vivo efficacy in a murine model of cardiac I/R
from the previously disclosed inhibitor CD38i
J. Med. Chem. 
Mitobridge (an Astellas Company), Cambridge, MA",MK-0159 , CD38,COCCO[C@@H]1CC[C@@H](NC(=O)c2cc(-c3cncs3)nc3[nH]ccc23)CC1,"InChI=1S/C20H24N4O3S/c1-26-8-9-27-14-4-2-13(3-5-14)23-20(25)16-10-17(18-11-21-12-28-18)24-19-15(16)6-7-22-19/h6-7,10-14H,2-5,8-9H2,1H3,(H,22,24)(H,23,25)/t13-,14-",JUVJFMVGYBBDKN-HDJSIYSDSA-N,False
57,MOTM-Infographic-JUNE.pdf,0,7,"TAS1553 | RNR
oral RNR subunit interaction inhibitor
Ph. I candidate in oncology
HTS and SBDD
Commun. Biol.
Taiho Pharmaceutical Co., Ltd., Tsukuba, JP",TAS1553 , RNR,Cc1ccc(F)c([C@@H](C)[C@H](NS(=O)(=O)c2ccc(Cl)cc2C(N)=O)c2n[nH]c(=O)o2)c1C,"InChI=1S/C20H20ClFN4O5S/c1-9-4-6-14(22)16(10(9)2)11(3)17(19-24-25-20(28)31-19)26-32(29,30)15-7-5-12(21)8-13(15)18(23)27/h4-8,11,17,26H,1-3H3,(H2,23,27)(H,25,28)/t11-,17+/m1/s1",DUYRWEBTZNUILI-DIFFPNOSSA-N,True
58,MOTM-Infographic-JUNE.pdf,0,8,"NTQ1062 | Akt
oral Akt inhibitor
Ph. I in advanced solid tumors
scaffold hopping and PK opt.
J. Med. Chem.
Nanjing Chia-Tai Tianqing Pharmaceutical Co., 
Ltd., Nanjing, CN",NTQ1062 , Akt,CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC(=O)N3)[C@H]2C[C@H]21)c1ccc(Cl)cc1,"InChI=1S/C25H31ClN6O2/c1-14(2)27-12-18(16-4-6-17(26)7-5-16)25(34)32-9-8-31(19-11-20(19)32)24-22-15(3)10-21(33)30-23(22)28-13-29-24/h4-7,13-15,18-20,27H,8-12H2,1-3H3,(H,28,29,30,33)/t15-,18-,19+,20-/m1/s1",RXNPEQZHMGFNAY-GEALJGNFSA-N,True
59,MOTM-Infographic-JUNE.pdf,0,9,"Apararenone | MR
oral nonsteroidal MR antagonist
Ph. II candidate in DN and NASH (discontinued)
previous literature and hypothesis-driven opt.
J. Med. Chem.
Mitsubishi Tanabe Pharma Corporation, 
Yokohama, JP",Apararenone , MR,CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O,"InChI=1S/C17H17FN2O4S/c1-17(2)16(21)20(13-7-4-11(18)5-8-13)14-9-6-12(10-15(14)24-17)19-25(3,22)23/h4-10,19H,1-3H3",AZNHWXAFPBYFGH-UHFFFAOYSA-N,True
60,MOTM-Infographic-JULY.pdf,0,0,"Compound 33 | PKG1α
intravenous PKG1α activator
satisfactory in vivo rat PK profile
from 2.9 M compounds HTS, SBDD and opt
J. Med. Chem.
Merck & Co., Inc., South San Francisco, CA",Compound 33 , PKG1α,O=C(O)c1ccc(CN2CCC[C@H](O[C@H](CO)c3cc(Cl)cc(Cl)c3)[C@@H]2c2ccccc2)c([N+](=O)[O-])c1,"InChI=1S/C27H26Cl2N2O6/c28-21-11-20(12-22(29)14-21)25(16-32)37-24-7-4-10-30(26(24)17-5-2-1-3-6-17)15-19-9-8-18(27(33)34)13-23(19)31(35)36/h1-3,5-6,8-9,11-14,24-26,32H,4,7,10,15-16H2,(H,33,34)/t24-,25+,26-/m0/s1",REDPQDQMPNUDEP-NXCFDTQHSA-N,True
61,MOTM-Infographic-JULY.pdf,0,1,"RP-6306 | PKMYT1
oral PKMYT1 inhibitor
three Ph. I studies currently ongoing
initial screen of 560 known kinase inhibitors
J. Med. Chem.
Repare Therapeutics, Inc., Ville St- Laurent, CA",RP-6306 , PKMYT1,Cc1cc2c(C(N)=O)c(N)n(-c3c(C)ccc(O)c3C)c2nc1C,"InChI=1S/C18H20N4O2/c1-8-5-6-13(23)10(3)15(8)22-16(19)14(17(20)24)12-7-9(2)11(4)21-18(12)22/h5-7,23H,19H2,1-4H3,(H2,20,24)",ARBRHWRTXPWZGN-UHFFFAOYSA-N,True
62,MOTM-Infographic-JULY.pdf,0,2,"BLU-945 | EGFRT790M/C797S
oral EGFR mutant inhibitor
Ph. I/II candidate oncology
>25k compound library screening and opt
J. Med. Chem.
Blueprint Medicines, Cambridge, MA",BLU-945 , EGFRT790M/C797S,CO[C@@H]1CCN(c2nccc(Nc3cc4c(C(C)C)ccc(N5C[C@H](CS(C)(=O)=O)[C@H]5C)c4cn3)n2)C[C@@H]1F,"InChI=1S/C28H37FN6O3S/c1-17(2)20-6-7-24(35-14-19(18(35)3)16-39(5,36)37)22-13-31-27(12-21(20)22)32-26-8-10-30-28(33-26)34-11-9-25(38-4)23(29)15-34/h6-8,10,12-13,17-19,23,25H,9,11,14-16H2,1-5H3,(H,30,31,32,33)/t18-,19-,23+,25-/m1/s1",LIMFPAAAIVQRRD-BCGVJQADSA-N,True
63,MOTM-Infographic-JULY.pdf,0,3,"SAGE-718 | NMDAR
oral NMDAR positive allosteric modulator
Ph. II candidate in neurology
from previously disclosed PAM and opt
J. Med. Chem.
Sage Therapeutics, Inc., Cambridge, MA",SAGE-718 , NMDAR,[H][C@@]12CC=C3C[C@@](C)(O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H]([C@H](C)CC[C@](C)(O)C(F)(F)F)CC[C@@]21[H],"InChI=1S/C27H43F3O2/c1-17(10-13-26(5,32)27(28,29)30)20-8-9-21-19-7-6-18-16-23(2,31)14-15-24(18,3)22(19)11-12-25(20,21)4/h6,17,19-22,31-32H,7-16H2,1-5H3/t17-,19+,20-,21+,22+,23+,24+,25-,26+/m1/s1",BVBRUQYHUXKZMQ-JNVAYQLDSA-N,True
64,MOTM-Infographic-JULY.pdf,0,4,"BI-4142 | HER2 exon 20 insertion
oral HER2 exon 20 mutants selective inhibitor
tumor regression in the HER2YVMA xenograft model
from 12k compounds in-house library screening 
and opt
Nat. Cancer
Boehringer Ingelheim RCV, Vienna, AT",BI-4142 , HER2 exon 20 insertion,C=CC(=O)N1CCN(c2ncc3ncnc(Nc4ccc(Oc5ccc6c(c5)ncn6C)c(C)c4)c3n2)CC1,"InChI=1S/C28H27N9O2/c1-4-25(38)36-9-11-37(12-10-36)28-29-15-22-26(34-28)27(31-16-30-22)33-19-5-8-24(18(2)13-19)39-20-6-7-23-21(14-20)32-17-35(23)3/h4-8,13-17H,1,9-12H2,2-3H3,(H,30,31,33)",JKBYBPNRTMHEGS-UHFFFAOYSA-N,False
65,MOTM-Infographic-JULY.pdf,0,5,"CHF-6366 | mAChRs & ADRB2
inhaled mAChR and ADRB2 agonist
Ph. I/II candidate in Asthma and COPD discontinued
soft drug design from previously disclosed lead 
MABA
J. Med. Chem.
Chiesi Farmaceutici S.p.A, Parma, IT",CHF-6366 , mAChRs & ADRB2,Cn1nc(C(=O)OCCCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1COc1cccc([C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)c1,"InChI=1S/C42H48N6O8/c1-47-30(23-34(46-47)41(52)54-21-6-5-18-43-24-36(50)32-12-14-35(49)40-33(32)13-15-38(51)44-40)26-55-31-11-7-10-29(22-31)39(28-8-3-2-4-9-28)45-42(53)56-37-25-48-19-16-27(37)17-20-48/h2-4,7-15,22-23,27,36-37,39,43,49-50H,5-6,16-21,24-26H2,1H3,(H,44,51)(H,45,53)/t36-,37-,39-/m0/s1",YWSIONULMMKTSJ-UZGNFBRWSA-N,True
66,MOTM-Infographic-JULY.pdf,0,6,"Compound 3f | FXIa
oral Factor XIa inhibitor
IV efficacy in rabbit AV shunt model
from literature starting point and SBDD
J. Med. Chem.
Janssen Research & Development, L.L.C., Spring 
House, PA",Compound 3f , FXIa,Cn1nncc1-c1cnn([C@H](CCOC(F)F)c2ccc(-c3c(-n4cc(Cl)nn4)ccc(Cl)c3F)c[n+]2[O-])c1,"InChI=1S/C23H18Cl2F3N9O2/c1-34-19(9-29-32-34)14-8-30-35(10-14)16(6-7-39-23(27)28)17-4-2-13(11-37(17)38)21-18(5-3-15(24)22(21)26)36-12-20(25)31-33-36/h2-5,8-12,16,23H,6-7H2,1H3/t16-/m1/s1",BETDGMHNHGHORO-MRXNPFEDSA-N,True
67,MOTM-Infographic-JULY.pdf,0,7,"MRTX0902 | SOS1:KRASG12C PPI
oral brain-penetrant SOS1:KRASG12C PPI inhibitor 
efficacy in MIA PaCa-2 tumor mouse xenograft model 
from literature starting point and opt
J. Med. Chem.
Mirati Therapeutics, San Diego, CA",MRTX0902 , SOS1:KRASG12C PPI,Cc1c(C#N)cccc1[C@@H](C)Nc1nnc(C)c2cnc(N3CCOCC3)cc12,"InChI=1S/C22H24N6O/c1-14-17(12-23)5-4-6-18(14)15(2)25-22-19-11-21(28-7-9-29-10-8-28)24-13-20(19)16(3)26-27-22/h4-6,11,13,15H,7-10H2,1-3H3,(H,25,27)/t15-/m1/s1",ILPWEAHQRAWJIU-OAHLLOKOSA-N,True
68,MOTM-Infographic-JULY.pdf,0,8,"Compound 14 | NNMT
elective NNMT inhibitor
100-times higher inhibitory activity than 
original peptide
peptide library screening, de novo design and SBDD
J. Med. Chem.
Shionogi Pharmaceutical Research Center, ",Compound 14 , NNMT,Cc1ccc2c(c1)cc([C@H]1C[C@H](n3nc(C)cc3CN)CN1C(=O)c1cnc3[nH]c(C)cc3c1)n2Cc1ccc(Cl)cc1,"InChI=1S/C34H34ClN7O/c1-20-4-9-30-24(10-20)14-31(40(30)18-23-5-7-27(35)8-6-23)32-15-29(42-28(16-36)12-22(3)39-42)19-41(32)34(43)26-13-25-11-21(2)38-33(25)37-17-26/h4-14,17,29,32H,15-16,18-19,36H2,1-3H3,(H,37,38)/t29-,32+/m0/s1",LJMIMBZGIMDSPE-BHDXBOSCSA-N,False
69,MOTM-Infographic-JULY.pdf,0,9,"CC-99677 | MK2
oral, covalent MK2 inhibitor
Ph. II candidate in ankylosing spondylitis
from previously disclosed MK2 inhibitor and SBDD 
Transl Res
Bristol Myers Squibb, Princeton, NJ",CC-99677 , MK2,CCOCc1cnc(Cl)nc1Oc1ccc2c(ccc3sc4c(c32)NC[C@@H](C)NC4=O)n1,"InChI=1S/C22H20ClN5O3S/c1-3-30-10-12-9-25-22(23)28-21(12)31-16-7-4-13-14(27-16)5-6-15-17(13)18-19(32-15)20(29)26-11(2)8-24-18/h4-7,9,11,24H,3,8,10H2,1-2H3,(H,26,29)/t11-/m1/s1",PYOQIOLRFIRRSO-LLVKDONJSA-N,True
70,MOTM-Infographic-August-2022.pdf,0,0,"Compound 3 | KRASG12R
KRASG12R mutant-selective covalent inhibitor
privileged arginine-reactive functional group
from previously disclosed K-Ras inhibitors
J. Am. Chem. Soc.
UCSF, San Francisco, CA",Compound 3 , KRASG12R,CC(=O)C(O)(O)C(=O)N1[C@@H]2CC[C@H]1CN(c1nc(OCC34CCCN3CCC4)nc3c(F)c(-c4cccc5cccc(Cl)c45)ncc13)C2,"InChI=1S/C35H36ClFN6O5/c1-20(44)35(46,47)32(45)43-22-10-11-23(43)18-41(17-22)31-25-16-38-29(24-8-2-6-21-7-3-9-26(36)27(21)24)28(37)30(25)39-33(40-31)48-19-34-12-4-14-42(34)15-5-13-34/h2-3,6-9,16,22-23,46-47H,4-5,10-15,17-19H2,1H3/t22-,23+",WMJCHIKSTOQGGL-ZRZAMGCNSA-N,False
71,MOTM-Infographic-August-2022.pdf,0,1,"AZD4831 | MPO
oral MPO covalent inhibitor
Ph. IIb/III candidate in HFpEF
previous literature and selectivity opt
J. Med. Chem.
AstraZeneca, Gothenburg, SE",AZD4831 , MPO,C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21,"InChI=1S/C15H15ClN4OS/c1-8(17)11-6-10(16)3-2-9(11)7-20-12-4-5-18-13(12)14(21)19-15(20)22/h2-6,8,18H,7,17H2,1H3,(H,19,21,22)/t8-/m1/s1",BHKKSKOHRFHHIN-MRVPVSSYSA-N,True
72,MOTM-Infographic-August-2022.pdf,0,2,"Obicetrapib | CETP
oral CETP inhibitor
Ph. III candidate in cardiology 
Signif. lipid lowering effect at 5 mg PO QD
Nat. Med.
Monash University, Clayton, AU
NewAmsterdam Pharma B.V., Naarden, NL",Obicetrapib , CETP,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC,"InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1",NRWORBQAOQVYBJ-GJZUVCINSA-N,True
73,MOTM-Infographic-August-2022.pdf,0,3,"SPH3127 | Renin
oral Renin Inhibitor
Ph. III candidate in essential hypertension
SBDD and PK profile opt
J. Med. Chem.
Mitsubishi Tanabe, Yokohama, JP
Shanghai Pharmaceuticals, Shanghai, CN",SPH3127 , Renin,COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21,"InChI=1S/C22H32N6O4/c1-14-5-8-17-19(26-27(20(17)25-14)11-4-9-24-22(30)31-3)15(2)28(16-6-7-16)21(29)18-13-23-10-12-32-18/h5,8,15-16,18,23H,4,6-7,9-13H2,1-3H3,(H,24,30)/t15-,18-/m1/s1",GRTDDIZIUSADLD-CRAIPNDOSA-N,True
74,MOTM-Infographic-August-2022.pdf,0,4,"Compound 19 | DHODH
oral DHODH inhibitor
tumor growth inhibition in xenograft models
from virtual screening and SBDD
J. Med. Chem.
Janssen, Spring House, PA",Compound 19 , DHODH,CCN1C(=NN(C2=C(C=C(C(=O)NC3=C(C)C=CN=C3Cl)C(=N2)O[C@@H](C)C(F)(F)F)F)C1=O)CO,"InChI=1S/C20H19ClF4N6O4/c1-4-30-13(8-32)29-31(19(30)34)16-12(22)7-11(18(28-16)35-10(3)20(23,24)25)17(33)27-14-9(2)5-6-26-15(14)21/h5-7,10,32H,4,8H2,1-3H3,(H,27,33)/t10-/m0/s1",XEDJGCIOZDHXOR-JTQLQIEISA-N,True
75,MOTM-Infographic-August-2022.pdf,0,5,"GNE-064 | SMARCA2/4 and PBRM1
oral SMARCA2/4 and PBRM1 selective inhibitor
oral PK observed in mouse
from 43k cmps HTS and SBDD
J. Med. Chem.
Genentech, South San Francisco, CA",GNE-064 , SMARCA2/4 and PBRM1,CC(=O)N1CCN(c2cc(-c3ccccc3O)nnc2N)C[C@H]1C,"InChI=1S/C17H21N5O2/c1-11-10-21(7-8-22(11)12(2)23)15-9-14(19-20-17(15)18)13-5-3-4-6-16(13)24/h3-6,9,11,24H,7-8,10H2,1-2H3,(H2,18,20)/t11-/m1/s1",FHRKRGDHMCCDEO-LLVKDONJSA-N,True
76,MOTM-Infographic-August-2022.pdf,0,6,"ACT-660602 | CXCR3
oral CXCR3 antagonist
efficacy in mice model of lung inflammation
from HTS and opt
J. Med. Chem.
Idorsia Pharmaceuticals Ltd., Allschwil, CH",ACT-660602 , CXCR3,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@H]2C)n1,"InChI=1S/C20H20F6N8OS/c1-10-8-32(4-5-33(10)14(35)9-34-12(3)29-11(2)31-34)16-15(30-18(36-16)20(24,25)26)13-6-27-17(28-7-13)19(21,22)23/h6-7,10H,4-5,8-9H2,1-3H3/t10-/m1/s1",JENUMEXEVAAAJX-SNVBAGLBSA-N,True
77,MOTM-Infographic-August-2022.pdf,0,7,"Compound 23 | Cat K
oral CAT K inhibitior
reduced uCTX-I levels in dog model
from opt of a previously disclosed cmpd
Bioorg. Med. Chem. Lett.
Merck, West Point, PA",Compound 23 , Cat K,N#CC1(NC(=O)[C@@H]2CCCC[C@H]2c2oc(-c3ccc(F)cc3)nc2-c2ccc(N3CCS(=O)(=O)CC3)cc2)CC1,"InChI=1S/C30H31FN4O4S/c31-22-9-5-21(6-10-22)29-33-26(20-7-11-23(12-8-20)35-15-17-40(37,38)18-16-35)27(39-29)24-3-1-2-4-25(24)28(36)34-30(19-32)13-14-30/h5-12,24-25H,1-4,13-18H2,(H,34,36)/t24-,25-/m1/s1",SBWFYUHMCHTQJT-JWQCQUIFSA-N,True
78,MOTM-Infographic-August-2022.pdf,0,8,"Compound 7 | 20S proteasome
oral 20S proteasome inhibitor
efficacy in stage II mouse model of HAT
3 million cmpd HTS and SBDD
J. Med. Chem.
Novartis Institutes for Biomedical Research, 
Emeryville, CA",Compound 7 , 20S proteasome,CO[C@@H](CO)CNC(=O)c1cc(Nc2cccc(F)c2F)c2cc(Cl)ccc2n1,"InChI=1S/C20H18ClF2N3O3/c1-29-12(10-27)9-24-20(28)18-8-17(13-7-11(21)5-6-15(13)25-18)26-16-4-2-3-14(22)19(16)23/h2-8,12,27H,9-10H2,1H3,(H,24,28)(H,25,26)/t12-/m1/s1",NTOVJWIULULGGI-GFCCVEGCSA-N,False
79,MOTM-Infographic-August-2022.pdf,0,9,"Compound 6 | YAP- TEAD
YAP-TEAD PPI inhibitor
single digit nanomolar potency
virtual screening and SBDD 
ChemMedChem
Novartis, Basel, Switzerland",Compound 6 , YAP- TEAD,COCCOc1ccc(C(N)=O)c(-c2c(Cl)ccc3c2C[C@@](CN)(c2ccccc2)O3)c1F,"InChI=1S/C25H24ClFN2O4/c1-31-11-12-32-20-9-7-16(24(29)30)22(23(20)27)21-17-13-25(14-28,15-5-3-2-4-6-15)33-19(17)10-8-18(21)26/h2-10H,11-14,28H2,1H3,(H2,29,30)/t25-/m1/s1",DMOHFURXRRTVGP-RUZDIDTESA-N,True
80,MOTM-Infographic-September-2022.pdf,0,0,"Ziftomenib | Menin-MLL1 PPI
oral menin-MLL1 inhibitor
Ph. I/II candidate in leukemia
from HTS and SBDD
Leukemia
Kura Oncology, San Diego, CA",Ziftomenib , Menin-MLL1 PPI,CNc1nc(NC2CCN(Cc3ccc4c(cc(C#N)n4C[C@H](C)N4CCN(S(C)(=O)=O)CC4)c3C)CC2)c2cc(CC(F)(F)F)sc2n1,"InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1",BGGALFIXXQOTPY-NRFANRHFSA-N,True
81,MOTM-Infographic-September-2022.pdf,0,1,"GB1211 | Galectin-3
oral galectin-3 inhibitor
Ph. I/II candidate in cancer and liver diseases 
LLE and PK opt. from a prev. clinical candidate 
J. Med. Chem.
Galecto Biotech, Gothenburg, SE",GB1211 , Galectin-3,OCC1O[C@H](Sc2cncc(Br)c2)[C@H](O)[C@@H](n2cc(-c3cc(F)c(F)c(F)c3)nn2)[C@@H]1O,"InChI=1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2/t14?,16-,17+,18+,19+/m0/s1",FNCLKJPMEFPXOR-QYCOUPDWSA-N,False
82,MOTM-Infographic-September-2022.pdf,0,2,"Compound 39 | GCN2
oral GCN2 kinase inhibitor
TGI in LL2 syngeneic mouse model
SAR opt. from literature starting point
J. Med. Chem.
RAPT Therapeutics, South San Francisco, CA",Compound 39 , GCN2,CNC(=O)[C@]1(C)CC[C@@H](Nc2ncc3c(Br)nn(-c4ccc(-c5nnc(C)s5)cc4)c3n2)C1,"InChI=1S/C22H23BrN8OS/c1-12-28-29-19(33-12)13-4-6-15(7-5-13)31-18-16(17(23)30-31)11-25-21(27-18)26-14-8-9-22(2,10-14)20(32)24-3/h4-7,11,14H,8-10H2,1-3H3,(H,24,32)(H,25,26,27)/t14-,22-/m1/s1",ASGMFNBUXDJWJJ-JLCFBVMHSA-N,True
83,MOTM-Infographic-September-2022.pdf,0,3,"GST-HG131 | PAPD5/PAPD7
oral HBV antigen inhibitor
Ph. I candidate for hepatitis B
SAR opt. of a previously disclosed inhibitor 
Bioorganic Med. Chem. Lett.
WuXi AppTec, Shanghai, CN",GST-HG131 , PAPD5/PAPD7,COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1[C@H](C(C)(C)C)CO2,"InChI=1S/C23H29NO7/c1-23(2,3)21-13-31-18-11-20(30-8-6-7-28-4)19(29-5)9-14(18)16-10-17(25)15(22(26)27)12-24(16)21/h9-12,21H,6-8,13H2,1-5H3,(H,26,27)/t21-/m0/s1",PQMAMDUBYCMNAT-NRFANRHFSA-N,True
84,MOTM-Infographic-September-2022.pdf,0,4,"Neflamapimod | p38α kinase
oral p38α kinase inhibitor
Ph. II candidate in neurology 
from SBDD and opt.
Nat. Commun.
EIP Pharma Inc, Boston, MA /  
Vertex, Cambridge, MA",Neflamapimod , p38α kinase,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H,VEPKQEUBKLEPRA-UHFFFAOYSA-N,True
85,MOTM-Infographic-September-2022.pdf,0,5,"AZD1390 | ATM kinase
oral ATM kinase inhibitor
Ph. I candidate oncology
biochem-based screen. and BBB penetration opt 
J. Pharmacol. Exp. Ther.
AstraZeneca, Cambridge, UK",AZD1390 , ATM kinase,CC(C)n1c(=O)n(C)c2cnc3cc(F)c(-c4ccc(OCCCN5CCCCC5)nc4)cc3c21,"InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3",VQSZIPCGAGVRRP-UHFFFAOYSA-N,True
86,MOTM-Infographic-September-2022.pdf,0,6,"Upacicalcet | CaSR
IV CaSR agonist
Ph. III candidate in secondary hyperparathyroidism 
identified from “kokumi-flavor” studies of peptides 
Mol. Pharmacol.
Sanwa Kagaku Kenkyusho, Mie, JP",Upacicalcet , CaSR,Cc1c(Cl)cc(S(=O)(=O)O)cc1NC(=O)NC[C@H](N)C(=O)O,"InChI=1S/C11H14ClN3O6S/c1-5-7(12)2-6(22(19,20)21)3-9(5)15-11(18)14-4-8(13)10(16)17/h2-3,8H,4,13H2,1H3,(H,16,17)(H2,14,15,18)(H,19,20,21)/t8-/m0/s1",LHEYGVSDVBEYQF-QMMMGPOBSA-N,True
87,MOTM-Infographic-September-2022.pdf,0,7,"CH7057288 | TRK
oral pan-TRK inhibitor
tumor regression NIH3T3/NTRK1 mice models 
from in-house library screening and SBDD
J. Med. Chem.
Chugai Pharmaceutical, Shizuoka, JP",CH7057288 , TRK,Cc1cc(C(=O)NC(C)(C)C)cc(C#Cc2ccc3c4c(oc3c2)C(C)(C)c2cc(NS(C)(=O)=O)ccc2C4=O)n1,"InChI=1S/C32H31N3O5S/c1-18-14-20(30(37)34-31(2,3)4)16-21(33-18)10-8-19-9-12-24-26(15-19)40-29-27(24)28(36)23-13-11-22(35-41(7,38)39)17-25(23)32(29,5)6/h9,11-17,35H,1-7H3,(H,34,37)",DCGOHGQJHJXBGW-UHFFFAOYSA-N,True
88,MOTM-Infographic-September-2022.pdf,0,8,"ICeD-2 | DPP9
oral DPP9 inhibitor
in vitro synergy with NNRTI for HIV
from 250k cmpd phenotypic screen
ACS Chem. Biol.
Merck, Rahway, NJ",ICeD-2 , DPP9,N[C@H](C(=O)N1Cc2ccccc2C1)[C@@H]1CC[C@@H](N2CCCC2)CC1,"InChI=1S/C20H29N3O/c21-19(15-7-9-18(10-8-15)22-11-3-4-12-22)20(24)23-13-16-5-1-2-6-17(16)14-23/h1-2,5-6,15,18-19H,3-4,7-14,21H2/t15-,18-,19-/m0/s1",SYXDQNGJEXFDND-SNRMKQJTSA-N,True
89,MOTM-Infographic-September-2022.pdf,0,9,"Vadadustat | HIF-PHD
oral HIF-PHD enzyme inhibitor
Ph. III candidate for anemia in CKD 
carboxylic acid class of HIF-PHD inhibitors
J. Pharmacol. Exp. Ther.
Akebia Therapeutics, Cambridge, MA",Vadadustat , HIF-PHD,O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,"InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)",JGRXMPYUTJLTKT-UHFFFAOYSA-N,True
90,MOTM-Infographic-October-2022-1.pdf,0,0,"sebetralstat | plasma kallikrein
oral, on-demand plasma kallikrein inhibitor 
Ph. III candidate for on-demand treatment 
of HAE attacks
opt. from a known starting point
J. Med. Chem.
KalVista Pharmaceuticals Ltd., Salisbury, U.K.",sebetralstat , plasma kallikrein,COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F,"InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34)",KGMPDQIYDKKXRD-UHFFFAOYSA-N,True
91,MOTM-Infographic-October-2022-1.pdf,0,1,"GDC-2394 | NLRP3
oral NLRP3 inhibitor
predicted human dose of 500 mg QD
LLE opt. and tox. mitig. from prev. clin. cand. 
J. Med. Chem.
Genentech, South San Francisco, CA",GDC-2394 , NLRP3,CN[C@@H]1COc2c(S(=O)(=O)NC(=O)Nc3c4c(cc5c3CCC5)CCC4)cnn2C1,"InChI=1S/C20H25N5O4S/c1-21-14-10-25-19(29-11-14)17(9-22-25)30(27,28)24-20(26)23-18-15-6-2-4-12(15)8-13-5-3-7-16(13)18/h8-9,14,21H,2-7,10-11H2,1H3,(H2,23,24,26)/t14-/m0/s1",NDRARVKETDZHBS-AWEZNQCLSA-N,True
92,MOTM-Infographic-October-2022-1.pdf,0,2,"compound 5g | CDK2
oral CDK2 Inhibitor
oral/IV PK observed in rats
in-house HTS and scaffold hopping
ACS Med. Chem. Lett.
Incyte Research Institute, Wilmington, DE",compound 5g , CDK2,*NS(=O)(=O)c1ccc(Nc2ncc3c(n2)N([C@@H]2CCC[C@@H](O)C2)C(=O)C32CC2)cc1,,,False
93,MOTM-Infographic-October-2022-1.pdf,0,3,"AZD1656 | glucokinase
oral glucokinase activator
Ph. II in renal transplant patients with DM2 
AZD1092 opt. to avoid Ames test liability
Sci. Transl. Med.
AstraZeneca, Gothenburg, SE",AZD1656 , glucokinase,COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1,"InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1",FJEJHJINOKKDCW-INIZCTEOSA-N,True
94,MOTM-Infographic-October-2022-1.pdf,0,4,"JNJ-64264681 | BTK
oral BTK inhibitor
Ph. I candidate in NHL/CLL patients
from Janssen cmp. collection screen and opt. 
J. Med. Chem.
Janssen, San Diego, CA",JNJ-64264681 , BTK,C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1NC(=O)N3c1cnc(CC(C)C)cc1C,"InChI=1S/C27H30N6O3S/c1-5-21(34)30-17-7-6-8-18(17)31-25(35)24-23-22-19(9-10-28-26(22)37-24)33(27(36)32-23)20-13-29-16(11-14(2)3)12-15(20)4/h5,9-10,12-14,17-18H,1,6-8,11H2,2-4H3,(H,30,34)(H,31,35)(H,32,36)/t17-,18+/m0/s1",OPLNLPWGEZNZFL-ZWKOTPCHSA-N,True
95,MOTM-Infographic-October-2022-1.pdf,0,5,"BI-0474 | KRASG12C
IP KRASG12Ci related to oral candidate BI 1823911 
TGI in NCI-H358 cancer xenograft mouse model 
from 13k cmpd. HSQC-based screen and SBDD 
J. Med. Chem.
Boehringer Ingelheim, Vienna, AT",BI-0474 , KRASG12C,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,"InChI=1S/C30H37N9O2S/c1-5-25(40)38-12-10-37(11-13-38)20-15-22(33-24(16-20)39-14-9-36(4)18-19(39)2)28-34-29(41-35-28)30(3)8-6-7-23-26(30)21(17-31)27(32)42-23/h5,15-16,19H,1,6-14,18,32H2,2-4H3/t19-,30-/m0/s1",CKAMBYUZKWQCKJ-ADSBAMQRSA-N,True
96,MOTM-Infographic-October-2022-1.pdf,0,6,"compound 57 | EGFRL858R
oral EGFRL858R inhibitor
efficacy in EGFR mutant mouse models
SBDD opt. from previously disclosed EGFRai
J. Med. Chem.
F. Hoffmann-La Roche, Basel, CH",compound 57 , EGFRL858R,CC1=C(C#CC2=CC=C(C=C2)CN3CCC(CC3)CO)C=C(C4=CN(C(C5=C6CCC7(CC7)N6C=N5)C(=O)NC8=NC=CS8)N=C14)C(F)F,"InChI=1S/C37H37F2N7O2S/c1-23-27(7-6-24-2-4-25(5-3-24)19-44-15-9-26(21-47)10-16-44)18-28(34(38)39)29-20-46(43-31(23)29)33(35(48)42-36-40-14-17-49-36)32-30-8-11-37(12-13-37)45(30)22-41-32/h2-5,14,17-18,20,22,26,33-34,47H,8-13,15-16,19,21H2,1H3,(H,40,42,48)",XGCQKFFIRIFVIZ-UHFFFAOYSA-N,True
97,MOTM-Infographic-October-2022-1.pdf,0,7,"AN15368 | CPSF3
oral CPSF3 inhibitor for Chagas
uniformly curative in naturally infected 
rhesus macaques
from benzoxaborole library screen and opt.
Nat. Microbiol.
Anacor Pharmaceuticals, Palo Alto, CA",AN15368 , CPSF3,Cc1c(C(=O)N[C@H](C(=O)OCC2CCOCC2)C(C)C)ccc2c1B(O)OC2,"InChI=1S/C20H28BNO6/c1-12(2)18(20(24)27-10-14-6-8-26-9-7-14)22-19(23)16-5-4-15-11-28-21(25)17(15)13(16)3/h4-5,12,14,18,25H,6-11H2,1-3H3,(H,22,23)/t18-/m0/s1",MCKPYEQRZUCJKI-SFHVURJKSA-N,True
98,MOTM-Infographic-October-2022-1.pdf,0,8,"UCB7362 | plasmepsin X
oral PMX inhibitor for malaria
50 mg QD/7 days estimated to be curative
from guanidine-based focused lib. screen. 
and SBDD
J. Med. Chem.
UCB Biopharma, Braine-l’Alleud, BE",UCB7362 , plasmepsin X,C[C@H]1C[C@@H](N2C(=N)N[C@](C)(c3cccc(NC(=O)c4cccc(C#N)c4)c3Cl)CC2=O)CCO1,"InChI=1S/C25H26ClN5O3/c1-15-11-18(9-10-34-15)31-21(32)13-25(2,30-24(31)28)19-7-4-8-20(22(19)26)29-23(33)17-6-3-5-16(12-17)14-27/h3-8,12,15,18H,9-11,13H2,1-2H3,(H2,28,30)(H,29,33)/t15-,18-,25-/m0/s1",AWSRDDSRQUJMAJ-LCAJTWGOSA-N,True
99,MOTM-Infographic-October-2022-1.pdf,0,9,"BAY-069 | BCAT1/2
oral BCAT1/2 inhibitor
favorable PK profile in rats
from 788762 cmpd. HTS and SBDD
J. Med. Chem.
Bayer Pharma AG, Berlin, DE",BAY-069 , BCAT1/2,Cc1ccccc1Oc1cc(-n2c(=O)cc(C(F)(F)F)[nH]c2=O)c2ccccc2c1Cl,"InChI=1S/C22H14ClF3N2O3/c1-12-6-2-5-9-16(12)31-17-10-15(13-7-3-4-8-14(13)20(17)23)28-19(29)11-18(22(24,25)26)27-21(28)30/h2-11H,1H3,(H,27,30)",UNSHMXUHOHBLIQ-UHFFFAOYSA-N,True
100,DH-MOTM-Poster-November-2022-R4.pdf,0,0,"systemic, oral DGAT2 inhibitor
Ph. II for NASH with fibrosis
opt. of liver-targeting candidate PF-06427878
J. Med. Chem., 02 November 2022
PFIZER, CAMBRIDGE, MA AND GROTON, CT
ervogastat
DGAT2","systemic, oral DGAT2 inhibitor",Ph. II for NASH with fibrosis,CCOc1cccnc1Oc1cncc(-c2ncc(C(=O)N[C@H]3CCOC3)cn2)c1,"InChI=1S/C21H21N5O4/c1-2-29-18-4-3-6-23-21(18)30-17-8-14(9-22-12-17)19-24-10-15(11-25-19)20(27)26-16-5-7-28-13-16/h3-4,6,8-12,16H,2,5,7,13H2,1H3,(H,26,27)/t16-/m0/s1",UKBQFBRPXKGJPY-INIZCTEOSA-N,True
101,DH-MOTM-Poster-November-2022-R4.pdf,0,1,"PTC258
mutant ELP1 pre-mRNA 
oral ELP1 ex20 splicing modulator
rescues motor coordination in FD mouse model
opt. from natural product from 1K cmpd screen
bioRxiv, 04 November 2022
MASS GENERAL / PTC THERAPEUTICS",PTC258,mutant ELP1 pre-mRNA ,Cc1c(C[C@H](C)N)sc2c(NCc3cccs3)cc(Cl)nc12,"InChI=1S/C16H18ClN3S2/c1-9(18)6-13-10(2)15-16(22-13)12(7-14(17)20-15)19-8-11-4-3-5-21-11/h3-5,7,9H,6,8,18H2,1-2H3,(H,19,20)/t9-/m0/s1",XBAVUBLRECEOPY-VIFPVBQESA-N,True
102,DH-MOTM-Poster-November-2022-R4.pdf,0,2,"sirpiglenastat
glutamine antimetabolite
IV/SC glutamine antimetabolite prodrug
Ph. I/IIa in advanced solid tumors
dual prodrug of natural product
Sci. Adv., 16 November 2022
JOHNS HOPKINS / DRACEN PHARMACEUTICALS",sirpiglenastat,glutamine antimetabolite,CC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(=O)C=NN)C(=O)OC(C)C,"InChI=1S/C22H29N5O5/c1-13(2)32-22(31)19(9-8-16(29)12-25-23)27-21(30)20(26-14(3)28)10-15-11-24-18-7-5-4-6-17(15)18/h4-7,11-13,19-20,24H,8-10,23H2,1-3H3,(H,26,28)(H,27,30)/t19-,20-/m0/s1",YAZHDYMIFSAJGI-PMACEKPBSA-N,False
103,DH-MOTM-Poster-November-2022-R4.pdf,0,3,"ENT-01
⍺-synuclein 
oral ⍺-synuclein aggregation inhibitor
completed Ph. IIb for PD + constipation
natural product
Sci. Adv., 16 November 2022
ENTERIN INC., PHILADELPHIA, PA",ENT-01,⍺-synuclein ,[H][C@]12C[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@]1([H])CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CC[C@@H](OS(=O)(=O)O)C(C)C)[C@]1([H])[C@H](O)C2,"InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1",UIRKNQLZZXALBI-MSVGPLKSSA-N,True
104,DH-MOTM-Poster-November-2022-R4.pdf,0,4,"mobocertinib
EGFR ex20 mutants
EGFR exon 20 mutant inhibitor, oral once-daily
FDA-approved for EGFR ex20+ NSCLC
from cellular screening + SBDD
Bioorg. Med. Chem. Lett., 21 November 2022
ARIAD/TAKEDA, CAMBRIDGE, MA",mobocertinib,EGFR ex20 mutants,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)",AZSRSNUQCUDCGG-UHFFFAOYSA-N,True
105,DH-MOTM-Poster-November-2022-R4.pdf,0,5,"compound 29
FGFR2/3
FGFR2/3 inhibitor
favorable PK profile in rats
opt. from HTS + SBDD & scaffold hopping
J. Med. Chem., 10 November 2022
INCYTE CORPORATION, WILMINGTON, DE",compound 29,FGFR2/3,CC(C)N1C=C(C=N1)C2=CN3C(=C(C=N3)C4=CN=CC(=C4)C(=O)NC)N=C2O[C@H]5CCOC5,"InChI=1S/C23H25N7O3/c1-14(2)29-11-17(9-26-29)20-12-30-21(28-23(20)33-18-4-5-32-13-18)19(10-27-30)15-6-16(8-25-7-15)22(31)24-3/h6-12,14,18H,4-5,13H2,1-3H3,(H,24,31)/t18-/m0/s1",XKKGIGFZDVPVNO-SFHVURJKSA-N,True
106,DH-MOTM-Poster-November-2022-R4.pdf,0,6,"compound 27 
CTPS1/2
CTPS1/2 inhibitor
in vivo anti-inflammatory activity in mice
in-house HTS of 240K library + opt.
J. Med. Chem., 30 November 2022
SYGNATURE, UK AND STEP PHARMA, FR",compound 27 ,CTPS1/2,CC(C)(C(=O)Nc1ccc(-c2cncc(C(F)(F)F)n2)cn1)c1csc(NS(=O)(=O)C2CC2)n1,"InChI=1S/C20H19F3N6O3S2/c1-19(2,15-10-33-18(27-15)29-34(31,32)12-4-5-12)17(30)28-16-6-3-11(7-25-16)13-8-24-9-14(26-13)20(21,22)23/h3,6-10,12H,4-5H2,1-2H3,(H,27,29)(H,25,28,30)",CZIDGRDZSFIUHX-UHFFFAOYSA-N,True
107,DH-MOTM-Poster-November-2022-R4.pdf,0,7,"compound 14d
β2-AMPK
β2-AMPK activator
in vivo efficacy in diabetic mouse model
scaffold hopping from MK-8722 + opt.
Bioorg. Med. Chem. Lett., 17 November 2022
SHIONOGI & CO., OSAKA, JP",compound 14d,β2-AMPK,[H][C@]12OC[C@@H](Oc3nc4nc(N[C@H]5CCc6cc(OCCOC)cc(F)c65)c(Cl)cc4[nH]3)[C@@]1([H])OC[C@H]2O,"InChI=1S/C24H26ClFN4O6/c1-32-4-5-33-12-6-11-2-3-15(19(11)14(26)7-12)27-22-13(25)8-16-23(29-22)30-24(28-16)36-18-10-35-20-17(31)9-34-21(18)20/h6-8,15,17-18,20-21,31H,2-5,9-10H2,1H3,(H2,27,28,29,30)/t15-,17+,18+,20+,21+/m0/s1",RWALQNUYYICDCM-UMBWAWJWSA-N,True
108,DH-MOTM-Poster-November-2022-R4.pdf,0,8,"TDI-11861
sAC
oral sAC inhibitor
intended for male contraception
opt. from TDI-10229 + SBDD
J. Med. Chem., 08 November 2022
TRI-I TDI/WEILL CORNELL MEDICINE, NY",TDI-11861,sAC,Nc1nc(Cl)cc(-c2nn(C(F)F)cc2Cc2ccccc2OCCN2CCOC[C@H]2CO)n1,"InChI=1S/C22H25ClF2N6O3/c23-19-10-17(27-22(26)28-19)20-15(11-31(29-20)21(24)25)9-14-3-1-2-4-18(14)34-8-6-30-5-7-33-13-16(30)12-32/h1-4,10-11,16,21,32H,5-9,12-13H2,(H2,26,27,28)/t16-/m1/s1",XVGSKZXXLKUEIO-MRXNPFEDSA-N,True
109,DH-MOTM-Poster-November-2022-R4.pdf,0,9,"EG-011
WASp
WASp activator
in vivo antitumor activity
fortuitous scaffold hopping from ibrutinib
bioRxiv, 25 November 2022
INSTITUTE OF ONCOLOGY RESEARCH, CH",EG-011,WASp,C=CC(=O)N1CCCC(n2c(=O)c3ncccc3n(Cc3ccc(Oc4ccccc4)cc3)c2=O)C1,"InChI=1S/C28H26N4O4/c1-2-25(33)30-17-7-8-21(19-30)32-27(34)26-24(11-6-16-29-26)31(28(32)35)18-20-12-14-23(15-13-20)36-22-9-4-3-5-10-22/h2-6,9-16,21H,1,7-8,17-19H2",JBKILBGEQHFIOB-UHFFFAOYSA-N,True
110,DH-MOTM-Poster-December-2022-R4.pdf,0,0,"resmetirom
THR-β
once daily, oral THR β-selective agonist
Ph. III for NASH
opt. of triiodothyronine
Company Announcement, December 19, 2022 
MADRIGAL PHARMACEUTICALS, PA",resmetirom,THR-β,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O,"InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)",FDBYIYFVSAHJLY-UHFFFAOYSA-N,True
111,DH-MOTM-Poster-December-2022-R4.pdf,0,1,"selective, bi-steric mTORC1 inhibitor
Ph. I/Ib for R/R solid tumors
opt. of rapalog+linker+mTOR inh
J. Med. Chem., December 19, 2022
REVOLUTION MEDICINES, REDWOOD CITY, CA
RMC-5552
mTORC1","selective, bi-steric mTORC1 inhibitor",Ph. I/Ib for R/R solid tumors,C[CH]C(O)OCCC(OC)C(C)=CC=CC=CC(C)C[CH]C[CH]12(OC)C[CH]3(OC)[CH]1(O)C14(C)=C[CH]56C=1(=C[CH]342O)C1[CH]523O[CH]164(O)C2C(C(C)CC1CCC(OCNCCOCCC(=O)N2CCC56=C(C=CC(CN7N=C(C8=CC9=C(C=C8)OC(N)=N9)C8=C(N)N=CN=C87)(=C5)C6)C2)C(OC)C1)C34.O,,,False
112,DH-MOTM-Poster-December-2022-R4.pdf,0,2,"inavolisib
mutant PI3K⍺
isoform-selective mutant PI3Kα degrader
oral <9 mg QD, Ph. III in HR+/HER2- BC
from cellular characterization of PI3Ki and opt.
J. Med. Chem., December 1, 2022
GENENTECH, SO. SF, CA",inavolisib,mutant PI3K⍺,C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O,"InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1",SGEUNORSOZVTOL-CABZTGNLSA-N,True
113,DH-MOTM-Poster-December-2022-R4.pdf,0,3,"BI 685509
sGC
oral sGC activator
Ph. II for CKD & DKD 
discovery not disclosed
J. Pharmacol. Exp. Ther., December 6, 2022
BOEHRINGER INGELHEIM PHARMACEUTICALS, CT",BI 685509,sGC,CCOc1c(C(=O)O)cnn1-c1cccc(-c2cccc(C)c2OCc2ccc3c(c2C)CCN(C2CCOCC2)C3)n1,"InChI=1S/C34H38N4O5/c1-4-42-33-29(34(39)40)19-35-38(33)31-10-6-9-30(36-31)28-8-5-7-22(2)32(28)43-21-25-12-11-24-20-37(16-13-27(24)23(25)3)26-14-17-41-18-15-26/h5-12,19,26H,4,13-18,20-21H2,1-3H3,(H,39,40)",KWNFFNFBUMFTHK-UHFFFAOYSA-N,True
114,DH-MOTM-Poster-December-2022-R4.pdf,0,4,"DN-1289
DLK/LZK
selective, CNS-penetrant dual DLK/LZK inhibitor
neuroprotective effects for in vivo + in 
vitro models for ALS
LBDD/SBDD + opt. from known molecule
J. Med. Chem., December 5, 2022",DN-1289,DLK/LZK,Nc1ncc(-c2cc(N3CCC(F)(F)C3)nc(N3C[C@@H]4C[C@H]3CO4)n2)nc1OC(F)F,"InChI=1S/C18H19F4N7O2/c19-16(20)31-15-14(23)24-5-12(25-15)11-4-13(28-2-1-18(21,22)8-28)27-17(26-11)29-6-10-3-9(29)7-30-10/h4-5,9-10,16H,1-3,6-8H2,(H2,23,24)/t9-,10-/m0/s1",AVWDJSXSWJBVBP-UWVGGRQHSA-N,False
115,DH-MOTM-Poster-December-2022-R4.pdf,0,5,"paltusotine
SST2
oral, non-peptide SST2 agonist
Ph. III for acromegaly + Ph. II for NETs
SAR on in-house library hit
ACS Med. Chem. Lett., December 10, 2022
CRINETICS PHARMACEUTICALS, CA",paltusotine,SST2,N#Cc1cccc(-c2ccc3ncc(-c4cc(F)cc(F)c4)c(N4CCC(N)CC4)c3c2)c1O,"InChI=1S/C27H22F2N4O/c28-19-10-18(11-20(29)13-19)24-15-32-25-5-4-16(22-3-1-2-17(14-30)27(22)34)12-23(25)26(24)33-8-6-21(31)7-9-33/h1-5,10-13,15,21,34H,6-9,31H2",GHILNKWBALQPDP-UHFFFAOYSA-N,True
116,DH-MOTM-Poster-December-2022-R4.pdf,0,6,"SPR720
GyrB
oral GyrB inhibitor
Ph. II for MAC pulmonary disease
HTS using a GyrB ATPase assay
bioRxiv, December 9, 2022
SPERO THERAPEUTICS, CAMBRIDGE, MA",SPR720,GyrB,CCNC(=O)Nc1nc2cc(-c3cnc(C(C)(C)OP(=O)(O)O)nc3)c(F)c([C@H]3CCCO3)c2[nH]1,"InChI=1S/C21H26FN6O6P/c1-4-23-20(29)28-19-26-13-8-12(16(22)15(17(13)27-19)14-6-5-7-33-14)11-9-24-18(25-10-11)21(2,3)34-35(30,31)32/h8-10,14H,4-7H2,1-3H3,(H2,30,31,32)(H3,23,26,27,28,29)/t14-/m1/s1",COTQDURISRILOR-CQSZACIVSA-N,True
117,DH-MOTM-Poster-December-2022-R4.pdf,0,7,"emraclidine
M4
M4 positive allosteric modulator
Ph. II for schizophrenia
discovery not disclosed
Lancet, December 17, 2022
CEREVEL THERAPEUTICS, CAMBRIDGE, MA",emraclidine,M4,Cc1cc(C)c2c(n1)CN(C(=O)CC1CN(c3ccnc(C(F)(F)F)c3)C1)C2,"InChI=1S/C20H21F3N4O/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14H,6,8-11H2,1-2H3",DTCZNKWBDTXEBS-UHFFFAOYSA-N,True
118,DH-MOTM-Poster-December-2022-R4.pdf,0,8,"compound 25
LRRK2
selective, CNS-penetrant LRRK2 kinase inhibitor 
preclinical, low projected human dose
opt. of MLi-2 series, from HTS
J. Med. Chem., December 7, 2022
MERCK & CO., BOSTON, MA",compound 25,LRRK2,CC(C)([C@@H]1CCN(C1)C2=CC(=NC=N2)N3C4=C(C=CC(=C4)[C@@]5(CC65CC6)C#N)C=N3)O,"InChI=1S/C24H26N6O/c1-22(2,31)18-5-8-29(12-18)20-10-21(27-15-26-20)30-19-9-17(4-3-16(19)11-28-30)24(14-25)13-23(24)6-7-23/h3-4,9-11,15,18,31H,5-8,12-13H2,1-2H3/t18-,24-/m1/s1",JCQABEJXHUSDMF-HOYKHHGWSA-N,True
119,DH-MOTM-Poster-December-2022-R4.pdf,0,9,"compound 49
CD73
orally bioavailable CD73 inhibitor
single agent, dose-dependent antitumor 
efficacy in mice
opt. of known CD73 inhibitor
J. Med. Chem., December 18, 2022",compound 49,CD73,C#C[C@@]1(O)[C@@H](COC(Cc2ccc(N3CCCNC3=O)cc2)(C(=O)O)C(=O)O)O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@@H]1O,"InChI=1S/C26H26ClN7O9/c1-2-25(41)15(43-20(17(25)35)34-12-30-16-18(28)31-23(27)32-19(16)34)11-42-26(21(36)37,22(38)39)10-13-4-6-14(7-5-13)33-9-3-8-29-24(33)40/h1,4-7,12,15,17,20,35,41H,3,8-11H2,(H,29,40)(H,36,37)(H,38,39)(H2,28,31,32)/t15-,17+,20-,25-/m1/s1",ROWSPNRRBJYDCU-IRJNKLFQSA-N,True
